Clinical Trial Update: The Combination Therapy With Ra-223 and Enzalutamide [Phase 2]

View source ↗

Summary

Phase 2 trial update on combining Ra-223 with Enzalutamide for castration-resistant prostate cancer with bone metastases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases
• Castration-resistant Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)
• Ra-223 (radium-223)

Snippet

Sponsor: Taro Iguchi, MD, PHD | Conditions: Castration-resistant Prostate Cancer, Bone Metastases | Phase 2 | Status: UNKNOWN